{
    "clinical_study": {
        "@rank": "30193", 
        "arm_group": [
            {
                "arm_group_label": "Arm N: Nivolumab", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 1 and 2: Nivolumab  solution intravenously 3mg/kg once every 2 weeks until disease progression or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Arm N+I: Nivolumab+Ipilimumab", 
                "arm_group_type": "Experimental", 
                "description": "Cohort 1 and 2: Nivolumab  solution 1mg/kg + Ipilimumab solution 3mg/kg intravenously once every 3 weeks for four doses\nFollowed by Nivolumab  solution 3mg/kg intravenously once every 2 weeks until disease progression or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Arm B: Bevacizumab", 
                "arm_group_type": "Active Comparator", 
                "description": "Cohort 2: Bevacizumab  solution 10 mg/kg intravenously once every 2 weeks until disease progression or unacceptable toxicity"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to understand the safety, tolerability and efficacy of Nivolumab\n      as a single agent or in combination with Ipilimumab versus Bevacizumab in patients diagnosed\n      with Recurrent Glioblastoma (GBM)."
        }, 
        "brief_title": "A Randomized Study of Nivolumab or Nivolumab Combined With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma(GBM)(CheckMate 143)", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Glioblastoma", 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Subjects with histologically confirmed Grade IV malignant glioma\n\n          -  Previous treatment with radiotherapy and temozolomide\n\n          -  Documented first recurrence of GBM\n\n          -  At least one measurable lesion\n\n          -  Karnofsky performance status (PS) \u2265 70\n\n        Exclusion Criteria:\n\n          -  More than one recurrence of GBM\n\n          -  Presence of extracranial metastatic or leptomeningeal disease\n\n          -  Active, known or suspected autoimmune disease\n\n          -  Prior Bevacizumab or other anti-vascular growth factor (VEGF) or anti-angiogenic\n             treatment\n\n          -  Clinically significant cardiovascular disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "264", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017717", 
            "org_study_id": "CA209-143", 
            "secondary_id": "2013-003738-34"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm N: Nivolumab", 
                    "Arm N+I: Nivolumab+Ipilimumab"
                ], 
                "intervention_name": "Nivolumab", 
                "intervention_type": "Biological", 
                "other_name": "BMS-936558"
            }, 
            {
                "arm_group_label": "Arm N+I: Nivolumab+Ipilimumab", 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "Yervoy", 
                    "BMS-734016"
                ]
            }, 
            {
                "arm_group_label": "Arm B: Bevacizumab", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Biological", 
                "other_name": "Avastin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Timothy Cloughesy, Site 0009", 
                    "phone": "310-794-3521"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "Ucla Neuro-Oncology Program"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Joachim Baehring, Site 0001", 
                    "phone": "203-785-5702"
                }, 
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Yale University School Of Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Solmaz Sahebjam, Site 0004", 
                    "phone": "813-745-4398"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "Moffitt Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alfredo Voloschin, Site 0002", 
                    "phone": "404-778-1900"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Winship Cancer Institute, Emory University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael Lim, Site 0008", 
                    "phone": "410-502-4081"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "The Johns Hopkins Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "David Reardon, Site 0006", 
                    "phone": "617-632-6749"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Antonio Omuro, Site 0003", 
                    "phone": "212-639-7523"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Ctr"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gordana Vlahovic, Site 0007", 
                    "phone": "919-668-2329"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Preston Robert Tisch Brain Tumor Center At Duke University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0005"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0035"
                }, 
                "facility": {
                    "address": {
                        "city": "Liverpool", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2017"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0034"
                }, 
                "facility": {
                    "address": {
                        "city": "East Bentleigh", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3165"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0033"
                }, 
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3084"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0032"
                }, 
                "facility": {
                    "address": {
                        "city": "Nedlands", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6009"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aarhus C", 
                        "country": "Denmark", 
                        "zip": "8000"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0057"
                }, 
                "facility": {
                    "address": {
                        "city": "Odense C", 
                        "country": "Denmark", 
                        "zip": "5000"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0010"
                }, 
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "zip": "40139"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0011"
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20133"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0012"
                }, 
                "facility": {
                    "address": {
                        "city": "Siena", 
                        "country": "Italy", 
                        "zip": "53100"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0013"
                }, 
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "zip": "10126"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0047"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0046"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28041"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0045"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28009"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0018"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "state": "Greater London", 
                        "zip": "NW1 2PG"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0015"
                }, 
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "state": "Greater Manchester", 
                        "zip": "M20 4BX"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0017"
                }, 
                "facility": {
                    "address": {
                        "city": "Wirral", 
                        "country": "United Kingdom", 
                        "state": "Merseyside", 
                        "zip": "L63 4JY"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Denmark", 
                "Italy", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Phase IIb, Open Label Study of Nivolumab or Nivolumab in Combination With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma (GBM)", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Germany: Ministry of Health", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Spain: Spanish Agency of Medicines", 
                "Denmark: Danish Dataprotection Agency", 
                "Denmark: Danish Medicines Agency", 
                "Denmark: The Danish National Committee on Biomedical Research Ethics", 
                "Sweden: Medical Products Agency", 
                "Sweden: The National Board of Health and Welfare", 
                "Sweden: Swedish Data Inspection Board", 
                "Sweden: Swedish Research Council", 
                "Sweden: Swedish National Council on Medical Ethics", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Italy: Ministry of Health", 
                "Italy: National Bioethics Committee", 
                "Italy: National Institute of Health", 
                "Italy: National Monitoring Centre for Clinical Trials - Ministry of Health", 
                "Italy: The Italian Medicines Agency", 
                "Switzerland: Federal Office of Public Health", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Canada: Health Canada", 
                "Poland: National Institute of Medicines", 
                "Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Cohort 1: Safety and tolerability based on drug related events leading to permanent discontinuation prior to completing 4 doses", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately up to 8 months"
            }, 
            {
                "description": "OS of Nivolumab, or Nivolumab in combination with Ipilimumab versus Bevacizumab.\nOverall Survival is defined as the time between the date of randomization and the date of death due to any cause", 
                "measure": "Cohort 2: Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "After 176 death events (approximately 44 months)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017717"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Comparing PFS between Nivolumab, or Nivolumab in combination with Ipilimumab versus Bevacizumab.\nPFS is defined as the time from randomization to the date of the first documented tumor progression or death due to any cause", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "After 176 death events (approximately 44 months)"
            }, 
            {
                "description": "Comparing ORR between Nivolumab, or Nivolumab in combination with Ipilimumab versus Bevacizumab.\nORR is defined as the number of subjects whose best overall response (BOR) is Complete Response (CR) or Partial Response (PR) divided by all randomized subjects", 
                "measure": "Objective Response Rate(ORR)", 
                "safety_issue": "No", 
                "time_frame": "After 176 death events (approximately 44 months)"
            }, 
            {
                "description": "Comparing OS between Nivolumab in combination with Ipilimumab versus Nivolumab", 
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "After 176 death events (Approximately 44 months)"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}